Will new biomarkers lead to "golden age" for mental health disorder diagnosis?
This article was originally published in Clinica
Executive Summary
Diagnosis of mental disorders, such as schizophrenia and depression, is slow, complicated and imprecise. Medtech firms are working to smooth the process with the development of definitive biomarker-based diagnostics with the aim of enabling earlier intervention and monitoring therapy to minimise side-effects. Phil Greenfield investigates